Thirty-Six-Week Real-World Effectiveness of Lebrikizumab for Different Anatomical Sites and Clinical Signs in Atopic Dermatitis: Results from a Prospective Japanese Study

Abstract: Background: Anti-interleukin-13 antibody lebrikizumab is highly effective and tolerable for atopic dermatitis (AD). However, real-world data are limited on its effectiveness for different anatomical sites and clinical signs.

Objective: To evaluate the effectiveness of lebrikizumab on different anatomical sites and clinical signs of AD.

Methods: This study included 162 patients with moderate-to-severe AD who received lebrikizumab for 36 weeks. Eczema Area and Severity Index (EASI) was assessed at weeks 0, 4, 12, 24, and 36 on four anatomical sites (head/neck, trunk, upper limbs, and lower limbs) and four clinical signs (erythema, edema/papulation, excoriation, and lichenification).

Results: Lebrikizumab consistently decreased EASI on all anatomical sites and all clinical signs through 36 weeks. Week 36 achievement rates of EASI 100 on the trunk and upper limbs (46.3% and 48.8%) were higher compared to head/neck and lower limbs (28.9% and 33.3%), respectively. The percentage reduction of EASI and achievement rates of EASI 75 and EASI 100 at each time-point were highest for excoriation among clinical signs; week 36 achievement rates of EASI 100 for erythema, edema/papulation, excoriation, and lichenification were 35.3%, 38.2%, 60.6%, and 37.1%, respectively.

Conclusions: Lebrikizumab consistently improves eruptions across all anatomical sites and clinical signs in AD throughout 36 weeks.